PSMA uptake (SUV(bw)max) and DWI MRI (ADCmax and ADCmin) were found to be distinct biomarkers able to differentiate between clinically significant PCa and normal prostatic tissue in naïve prostate cancer patients with a Gleason Score ≥7 [34,35]. This evidence concerns the gene FOLH1 and prostate carcinoma.